BENEVOLENTAI Stock Slides 9% So Far On Wednesday, Underperforms Market
BENEVOLENTAI, a London-based, clinical-stage AI drug discovery and development firm, has seen its stock experience significant instability. On Wednesday, its shares saw an alarming drop of 9.22% to EUR1.28, coinciding with a decline in the AEX-Index which fell 0.44% to EUR776.37. BENEVOLENTAI’s Current Financial Stature As of the last close, BENEVOLENTAI was revealed to be…